Medullary Thyroid Cancer: Management Guidelines

Абдулхабирова, Ф. М.; Бельцевич, Д. Г.; Ванушко, В Э; Дедов, И И; Кузнецов, Н С; Melnichenko, Galina; Platonova, Nadezhda; Rumyantsev, P O; Трошина, Е. А.; Tyulpakov, A. N.; Фадеев, В. В.; Abrosimov, Alexander; Ильин, А. А.; Исаев, П. А.; Medvedev, V. S.; Rumyantseva, U V; Brzhezovskiy, V Zh; Кропотов, М. А.; Lyubchenko, L. N.; Podvyaznikov, S O; Polyakov, V.G.; Романов, И. С.; Subramanian, Subbaya; Tyulyandin, S. A.; Ol'shanskiy, V O; Reshetov, I.; Makhson, A N; Bondarenko, V O; Ветшев, П С; Glezerov, E A; Zaletaev, D. V.; Ivanov, Yu. V.; Кожанов, Л Г; Солдатов, И. В.; Kharnas, Sergey S.; Barchuk, A S; Bershteyn, Lev; Бубнов, А Н; Sleptsov, I V; Chernikov, Roman; Grineva, Elena; Manikhas, Georgy M.; Romanchishen, A F; Коренев, С. В.; Vikhlyanov, I. V.; Gashchenko, A D; Дворниченко, В. В.; Kiyaev, A V; Privalov, V. A.; Yaytsev, S V; Svetitskiy, P V; Khasanov, R. Sh.; Цветаев, В А; Choynzonov, E. L.; Шевченко, С. П.

doi:10.14341/2306-3513-2012-1-5-17

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Это исследование может повлиять на показания к ТАБ, поэтому должно проводиться на первичном этапе обследования. Также и в проекте национальных клинических рекомендаций по диагностике и лечению медуллярного рака щитовидной железы рекомендовано измерение уровня базального кальцитонина всем пациентам с опухолями щитовидной железы (рекомендация 1.4) [20].…”

Section: диагноз при выпискеunclassified

Medullary thyroid cancer. Returning to the need to determine the preoperative basal calcitonin level in patients with thyroid nodular pathology

et al. 2019

View full text Add to dashboard Cite

There are International and Russian guidelines for the diagnosis and treatment of medullary thyroid carcinoma. There is a recommendation to determine the basal level of calcitonin for all patients with nodular thyroid disease at the all of these documents. However, this test is not performed for this category of patients routinely even in large clinics for a number of reasons, the main one, which seems to be an economic issue. Six months ago a patient addressed to our clinic who underwent surgical treatment for a papillary carcinoma (follicular variant) of the thyroid gland in the volume of thyroidectomy with pre-tracheal lymphodissection and subsequent course of radioiodine therapy at the place of residence. A relapse of the disease was suspected on the control examination at the place of residence and the patient was sent for consultation to the polyclinic of the N.N. Blokhin National Medical Research Center of Oncology. In our clinic, diagnostic studies were carried out, including a revision of the finished cytological and histological preparations and a conclusion was obtained – medullary carcinoma of the thyroid. Determination of basal level of calcitonin in serum showed a value of 1292 pg/ml. The level of basal calcitonin significantly decreased after repeated surgical treatment. This case shows that in order to avoid such mistake, which is described in our clinical case, it seems necessary to follow the national recommendations, international standards to determine the level of basal calcitonin for all patients with thyroid nodal pathology who consulted and treated in medical institutions.

show abstract

Section: диагноз при выпискеunclassified

Medullary thyroid cancer. Returning to the need to determine the preoperative basal calcitonin level in patients with thyroid nodular pathology

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Согласно национальным рекомендациям такой уровень кальцитонина (менее 150 пг/мл) может быть ассоци ирован с местнораспространенным процессом. Отдаленные метастазы в данной ситуации возможны, но обычно небольшого размера и, как правило, трудно верифицируемы [11].…”

Section: Abstract: Medullary Thyroid Cancer Renal Cancer Case Reportunclassified

“…В настоящее время состояние пациента удовлетворительное, продолжает получать заместительную терапию L-тироксином, доза снижена до 88 мкг в сутки, так как уровень ТТГ был 0,36 мЕД/л. Известно, что пациентам с МРЩЖ после тиреоидэктомии показана заместительная терапия левотироксином с целевым диапазоном уровня ТТГ в пределах от 0,5 до 2,5 мЕД/л, супрессивная терапия не показана [11]. Показатели гликемии (гликированный гемоглобин 6,1% от 02.2017), липидного спектра и артериального давления стабилизированы в пределах рекомендованных значений.…”

Section: исход и результаты последующего наблюденияunclassified

Combination of medullary thyroid cancer and renal cell carcinoma in one patient

Dolinskaya¹,

Александровна²,

Шевченко

et al. 2018

Clin Exp Thyroid

View full text Add to dashboard Cite

Patients who received treatment for the first malignant neoplasm remain in the group at increased risk of developing a second primary tumor throughout their later life. A rare case of medullary thyroid cancer and renal cell carcinoma of the kidney is described in one patient. Medullary thyroid cancer is an orphan disease. The patient and his first-line relatives underwent molecular-genetic testing, the presence of a hereditary form of medullary cancer was excluded. During the observation, malignant kidney formation was detected, and surgical treatment was performed. The patient because of treatment and surveillance does not have data for the progression of thyroid cancer and kidney cancer, compensation for concomitant diseases has been achieved. When observing patients with medullary thyroid cancer, it is necessary to use the existing modern diagnostic arsenal, including positron emission tomography, since patients remain in the group at increased risk of disease progression and development of the second tumor throughout the entire subsequent life. In addition, this case clearly illustrates the need for a routine study of calcitonin as a diagnostic marker for the progression of medullary thyroid cancer.

show abstract

2016 Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment

et al. 2017

View full text Add to dashboard Cite

В представленных клинических рекомендациях обсуждаются современные подходы к диагностике и лечению дифференцированного рака щитовидной железы у взрослых. Изменения в настоящей редакции Клинических рекомендаций касаются показаний к пункционной биопсии, скринингового определения концентрации кальцитонина, унификации заключений цитологического исследования, новых подходах к послеоперационной динамической стратификации риска рецидива, показаний к супрессивной и заместительной терапии, таргетной терапии йоднегативных форм дифференцированного рака щитовидной железы.

show abstract

Medullary Thyroid Cancer: Management Guidelines

Cited by 5 publications

References 0 publications

Medullary thyroid cancer. Returning to the need to determine the preoperative basal calcitonin level in patients with thyroid nodular pathology

Medullary thyroid cancer. Returning to the need to determine the preoperative basal calcitonin level in patients with thyroid nodular pathology

Combination of medullary thyroid cancer and renal cell carcinoma in one patient

2016 Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment

Contact Info

Product

Resources

About